|
1
|
Torre LA, Siegel RL and Jemal A: Lung
Cancer Statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Institute of Health Information and
Statistics of the Czech Republic, . Czech Health Statistics Year
Book 2013UZIS CR. Prague: 2014
|
|
3
|
Travis WD: Pathology of lung cancer. Clin
Chest Med. 32:669–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Socinski MA, Obasaju C, Gandara D, Hirsch
FR, Bonomi P, Bunn P, Kim ES, Langer CJ, Natale RB, Novello S, et
al: Clinicopathologic features of advanced squamous NSCLC. J Thorac
Oncol. 11:1411–1422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Olaussen KA and Postel-Vinay S: Predictors
of chemotherapy efficacy in non-small-cell lung cancer: A
challenging landscape. Ann Oncol. 27:2004–2016. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Inamura K and Ishikawa Y: MicroRNA in lung
cancer: Novel biomarkers and potential tools for treatment. J Clin
Med. 5:pii: E362016. View Article : Google Scholar
|
|
7
|
Griffiths-Jones S, Saini HK, van Dongen S
and Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids
Res. 36(Database Issue): D154–D158. 2008.PubMed/NCBI
|
|
8
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sobin LH, Gospodarowicz MK and Wittekind
Ch: TNM Classification of Malignant Tumours. 7th. Wiley-Blackwell;
Chichester: 2010
|
|
10
|
Kalfert D, Pesta M, Kulda V, Topolcan O,
Ryska A, Celakovsky P, Laco J and Ludvikova M: MicroRNA profile in
site-specific head and neck squamous cell cancer. Anticancer Res.
35:2455–2463. 2015.PubMed/NCBI
|
|
11
|
Smid D, Kulda V, Srbecka K, Kubackova D,
Dolezal J, Daum O, Kucera R, Topolcan O, Treska V, Skalicky T and
Pesta M: Tissue microRNAs as predictive markers for gastric cancer
patients undergoing palliative chemotherapy. Int J Oncol.
48:2693–2703. 2016.PubMed/NCBI
|
|
12
|
Mazumdar M and Glassman JR: Categorizing a
prognostic variable: Review of methods, code for easy
implementation and applications to decision-making about cancer
treatments. Stat Med. 19:113–132. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Faraggi D and Simon R: A simulation study
of cross-validation for selecting an optimal cutpoint in univariate
survival analysis. Stat Med. 15:2203–2213. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vlachos IS, Paraskevopoulou MD, Karagkouni
D, Georgakilas G, Vergoulis T, Kanellos I, Anastasopoulos IL,
Maniou S, Karathanou K, Kalfakakou D, et al: DIANA-TarBase v7.0:
Indexing more than half a million experimentally supported
miRNA:mRNA interactions. Nucleic Acids Res. 43(Database Issue):
D153–D159. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vlachos IS, Zagganas K, Paraskevopoulou
MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T and
Hatzigeorgiou AG: DIANA-miRPath v3.0: Deciphering microRNA function
with experimental support. Nucleic Acids Res. 43:W460–W466. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khan J, Lieberman JA and Lockwood CM:
Variability in, variability out: Best practice recommendations to
standardize pre-analytical variables in the detection of
circulating and tissue microRNAs. Clin Chem Lab Med. 55:608–621.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cui R, Kim T, Fassan M, Meng W, Sun HL,
Jeon YJ, Vicentini C, Tili E, Peng Y and Scarpa A: MicroRNA-224 is
implicated in lung cancer pathogenesis through targeting caspase-3
and caspase-7. Oncotarget. 6:21802–21815. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang H, Zhu LJ, Yang YC, Wang ZX and Wang
R: MiR-224 promotes the chemoresistance of human lung
adenocarcinoma cells to cisplatin via regulating G1/S transition
and apoptosis by targeting p21(WAF1/CIP1). Br J Cancer.
111:339–354. 2014. View Article : Google Scholar
|
|
19
|
Zhu D, Chen H, Yang X, Chen W, Wang L, Xu
J and Yu L: Decreased microRNA-224 and its clinical significance in
non-small cell lung cancer patients. Diagn Pathol. 9:1982014.
View Article : Google Scholar
|
|
20
|
Wang L, Liu W, Zhang YP and Huang XR: The
miR-224 promotes non-small cell lung cancer cell proliferation by
directly targeting RASSF8. Eur Rev Med Pharmacol Sci. 21:3223–3231.
2017.
|
|
21
|
Xie X, Liu H, Wang M, Ding F, Xiao H, Hu
F, Hu R and Mei J: miR-342-3p targets RAP2B to suppress
proliferation and invasion of non-small cell lung cancer cells.
Tumour Biol. 36:5031–5038. 2015. View Article : Google Scholar
|
|
22
|
Tai MC, Kajino T, Nakatochi M, Arima C,
Shimada Y, Suzuki M, Miyoshi H, Yatabe Y, Yanagisawa K and
Takahashi T: miR-342-3p regulates MYC transcriptional activity via
direct repression of E2F1 in human lung cancer. Carcinogenesis.
36:1464–1473. 2015.
|
|
23
|
Takahashi K, Yokota SI, Tatsumi N, Fukami
T, Yokoi T and Nakajima M: Cigarette smoking substantially alters
plasma microRNA profiles in healthy subjects. Toxicol Appl
Pharmacol. 272:154–160. 2013. View Article : Google Scholar
|
|
24
|
Rokavec M, Li H, Jiang L and Hermeking H:
The p53/miR-34 axis in development and disease. J Mol Cell Biol.
6:214–230. 2014. View Article : Google Scholar
|
|
25
|
Okada N, Lin CP, Ribeiro MC, Biton A, Lai
G, He X, Bu P, Vogel H, Jablons DM, Keller AC, et al: A positive
feedback between p53 and miR-34 miRNAs mediates tumor suppression.
Genes Dev. 28:438–450. 2014. View Article : Google Scholar
|
|
26
|
Navarro F and Lieberman J: miR-34 and p53:
New insights into a complex functional relationship. PLoS One.
10:e01327672015. View Article : Google Scholar
|
|
27
|
Ma ZL, Hou PP, Li YL, Wang DT, Yuan TW,
Wei JL, Zhao BT, Lou JT, Zhao XT, Jin Y and Jin YX: MicroRNA-34a
inhibits the proliferation and promotes the apoptosis of non-small
cell lung cancer H1299 cell line by targeting TGFβR2. Tumour Biol.
36:2481–2490. 2015. View Article : Google Scholar
|
|
28
|
Gallardo E, Navarro A, Viñolas N, Marrades
RM, Diaz T, Gel B, Quera A, Bandres E, Garcia-Foncillas J, Ramirez
J and Monzo M: miR-34a as a prognostic marker of relapse in
surgically resected non-small-cell lung cancer. Carcinogenesis.
30:1903–1909. 2009. View Article : Google Scholar
|
|
29
|
Franchina T, Amodeo V, Bronte G, Savio G,
Ricciardi GR, Picciotto M, Russo A, Giordano A and Adamo V:
Circulating miR-22, miR-24 and miR-34a as novel predictive
biomarkers to pemetrexed-based chemotherapy in advanced non-small
cell lung cancer. J Cell Physiol. 229:97–99. 2014.
|
|
30
|
Goto Y, Nishikawa R, Kojima S, Chiyomaru
T, Enokida H, Inoguchi S, Kinoshita T, Fuse M, Sakamoto S, Nakagawa
M, et al: Tumour-suppressive microRNA-224 inhibits cancer cell
migration and invasion via targeting oncogenic TPD52 in prostate
cancer. FEBS Lett. 588:1973–1982. 2014. View Article : Google Scholar
|
|
31
|
Zhang Y, Li CF, Ma LJ, Ding M and Zhang B:
MicroRNA-224 aggrevates tumor growth and progression by targeting
mTOR in gastric cancer. Int J Oncol. 49:1068–1080. 2016.
|
|
32
|
Adamopoulos PG, Kontos CK, Rapti SM,
Papadopoulos IN and Scorilas A: miR-224 overexpression is a strong
and independent prognosticator of short-term relapse and poor
overall survival in colorectal adenocarcinoma. Int J Oncol.
46:849–859. 2015. View Article : Google Scholar
|
|
33
|
Cui R, Meng W, Sun HL, Kim T, Ye Z, Fassan
M, Jeon YJ, Li B, Vicentini C, Peng Y, et al: MicroRNA-224 promotes
tumor progression in nonsmall cell lung cancer. Proc Natl Acad Sci
USA. 112:pp. E4288–E4297. 2015; View Article : Google Scholar
|
|
34
|
Tay Y, Rinn J and Pandolfi PP: The
multilayered complexity of ceRNA crosstalk and competition. Nature.
505:344–352. 2014. View Article : Google Scholar
|
|
35
|
Zhao Z, Zhang L, Yao Q and Tao Z: miR-15b
regulates cisplatin resistance and metastasis by targeting PEBP4 in
human lung adenocarcinoma cells. Cancer Gene Ther. 22:108–114.
2015. View Article : Google Scholar
|
|
36
|
Lin L, Tu HB, Wu L, Liu M and Jiang GN:
MicroRNA-21 regulates non-small cell lung cancer cell invasion and
chemo-sensitivity through SMAD7. Cell Physiol Biochem.
38:2152–2162. 2016. View Article : Google Scholar
|
|
37
|
Wang S, Su X, Bai H, Zhao J, Duan J, An T,
Zhuo M, Wang Z, Wu M, Li Z, et al: Identification of plasma
microRNA profiles for primary resistance to EGFR-TKIs in advanced
non-small cell lung cancer (NSCLC) patients with EGFR activating
mutation. J Hematol Oncol. 8:1272015. View Article : Google Scholar
|
|
38
|
Song C, Lu P, Sun G, Yang L and Wang Z and
Wang Z: miR-34a sensitizes lung cancer cells to cisplatin via
p53/miR-34a/MYCN axis. Biochem Biophys Res Commun. 482:22–27. 2017.
View Article : Google Scholar
|
|
39
|
Chen C, Zhao Z, Liu Y and Mu D:
microRNA-99a is downregulated and promotes proliferation, migration
and invasion in non-small cell lung cancer A549 and H1299 cells.
Oncol Lett. 9:1128–1134. 2015.
|
|
40
|
Ma Y, Li X, Cheng S, Wei W and Li Y:
MicroRNA-106a confers cisplatin resistance in non-small cell lung
cancer A549 cells by targeting adenosine triphosphatase-binding
cassette A1. Mol Med Rep. 11:625–632. 2015. View Article : Google Scholar
|
|
41
|
Zhang Z, Zhang L, Yin ZY, Fan XL, Hu B,
Wang LQ and Zhang D: miR-107 regulates cisplatin chemosensitivity
of A549 non small cell lung cancer cell line by targeting cyclin
dependent kinase 8. Int J Clin Exp Pathol. 7:7236–7241. 2014.
|
|
42
|
Zhang N, Su Y and Xu L: Targeting PKCε by
miR-143 regulates cell apoptosis in lung cancer. FEBS Lett.
587:3661–3667. 2013. View Article : Google Scholar
|
|
43
|
Gu XY, Wang J, Luo YZ, Du Q, Li RR, Shi H
and Yu TP: Down-regulation of miR-150 induces cell proliferation
inhibition and apoptosis in non-small-cell lung cancer by targeting
BAK1 in vitro. Tumour Biol. 35:5287–5293. 2014. View Article : Google Scholar
|
|
44
|
Cao J, He Y, Liu HQ, Wang SB, Zhao BC and
Cheng YS: MicroRNA 192 regulates chemo-resistance of lung
adenocarcinoma for gemcitabine and cisplatin combined therapy by
targeting Bcl-2. Int J Clin Exp Med. 8:12397–12403. 2015.
|
|
45
|
Yu T, Li J, Yan M, Liu L, Lin H, Zhao F,
Sun L, Zhang Y, Cui Y, Zhang F, et al: MicroRNA-193a-3p and −5p
suppress the metastasis of human non-small-cell lung cancer by
downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway.
Oncogene. 34:413–423. 2015. View Article : Google Scholar
|
|
46
|
Ye L, Wang H and Liu B: miR-211 promotes
non-small cell lung cancer proliferation by targeting SRCIN1.
Tumour Biol. 37:1151–1157. 2016. View Article : Google Scholar
|
|
47
|
Xie J, Yu F, Li D, Zhu X, Zhang X and Lv
Z: MicroRNA-218 regulates cisplatin (DPP) chemosensitivity in
non-small cell lung cancer by targeting RUNX2. Tumour Biol.
37:1197–1204. 2016. View Article : Google Scholar
|
|
48
|
Garofalo M, Di Leva G, Romano G, Nuovo G,
Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P,
et al: miR-221&222 regulate TRAIL resistance and enhance
tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell.
16:498–509. 2009. View Article : Google Scholar
|
|
49
|
Berghmans T, Ameye L, Willems L, Paesmans
M, Mascaux C, Lafitte JJ, Meert AP, Scherpereel A, Cortot AB,
Cstoth I, et al: Identification of microRNA-based signatures for
response and survival for non-small cell lung cancer treated with
cisplatin-vinorelbine A ELCWP prospective study. Lung Cancer.
82:340–345. 2013. View Article : Google Scholar
|
|
50
|
Fiedler SD, Carletti MZ and Christenson
LK: Quantitative RT-PCR methods for mature microRNA expression
analysis. Methods Mol Biol. 630:49–64. 2010. View Article : Google Scholar
|
